Preview

Атеротромбоз

Расширенный поиск

ОЦЕНКА ЧУВСТВИТЕЛЬНОСТИ К КЛОПИДОГРЕЛУ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ

https://doi.org/10.21518/2307-1109-2015-2-95-106

Полный текст:

Аннотация

Обзор посвящен лабораторной оценке действия клопидогрела у ИБС. Приведены результаты основных крупных исследований, продемонстрировавших связь уровня остаточной реактивности тромбоцитов и нарушений фармакогенетики препарата с развитием ишемических осложнений. Рассмотрены предложения международных экспертных организаций по оценке чувствительности к клопи-догрелу и возможной модификации антитромбоцитарного лечения.

Об авторе

А. Л. КОМАРОВ
ФГБУ «Российский кардиологический научно-производственный комплекс» Министерства здравоохранения РФ, Москва
Россия


Список литературы

1. Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST ЭКГ. Рекомендации ВНОК. Ред. Руда М.Я. Кардиоваскулярная терапия и профилактика, Приложение 1, 2007, 6(8): 415-500.

2. Национальные рекомендации по лечению ОКС без стойкого подъема ST на ЭКГ Рекомендации ВНОК. Ред. Грацианский Н.А. Кардиоваскулярная терапия и профилактика, Приложение 1, 2006, 5:411-440.

3. Национальные рекомендации по антитромботической терапии у больных со стабильными проявлениями атеротромбоза. Кардиоваскулярная терапия и профилактика, Приложение 6, 2009, 8(6).

4. 2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal doi:10.1093/eurheartj/ehu278.

5. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction.JACC, 61,4: 78-140.

6. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology, Volume 64, Issue 24, e139-e228.

7. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment eleva-tion. European Heart Journal, 2012, 33: 2569-2619 doi:10.1093/eurheartj/ehs215.

8. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation European Heart Journal doi:10.1093/eurheartj/ehv320.

9. Aradi D, Storey RF, Komocsi A et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal, 2014, 35, 209-215 doi:10.1093/eurheartj/eht375.

10. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Supplementary material. http://eurheartj.oxfordjournals.org/content/ehj/suppl/20 13/08/23/eht375.DC1/eht375supp.pdf.

11. Udaya S Tantry, Laurent Bonello, Daniel Aradi, for the Working Group on On-Treatment Platelet Reactivity. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding.J Am Coll Cardiol, 2013,62:2261-73.

12. Stone GW, Witzenbichler B, Weisz G et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet, 2013, 382: 614-623.

13. Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.J Am Coll Cardiol, 2006,7,48(9): 1742-50.

14. Buonamici P, Marcucci R, Migliorini A, Gensini G, Santini A, Paniccia R, Moschi G, Gori A, Abbate R, Antoniucci D. Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis. JAm Coll Cardiol, 2007, 49: 2312-7.

15. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review andmeta-analysis.AmHeartJ, 2007, Aug. 154(2): 221-31.

16. Aradi D, Collet J, Mair J et al. Platelet function testing in acute cardiac care — is there a role for prediction or prevention of stent thrombosis and bleeding? Thromb Haemost, 2015, 113:221-230.

17. Hulot J, Collet J, Silvain J et al. Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration: A Systematic Meta-Analysis.J Am Coll Cardiol, 2010, Jul 6, 56(2): 134-43. doi: 10.1016/j.jacc.2009.12.071.

18. Stockbridge N. FDA Letter of Approval: May 5, 2009, NDA 20-839/S-040. U.S. Food and Drug Administration. URL: http://www.accessdata.fda.gov/ drugsatfda_docs/appletter/2009/020839s040ltr.pdf. Accessed April 29, 2010.

19. Sarno G, Lagerqvist B, Nilsson J et al. Stent Thrombosis in New-Generation Drug-Eluting Stents in Patients With STEMI Undergoing Primary PCI A Report From SCAAR.J Am Coll Cardiol, 2014, 64: 16-24.

20. Loh JP, Torguson R, Pendyala LK et al. Impact of Early Versus Late Clopidogrel Discontinuation on Stent Thrombosis Following Percutaneous Coronary Intervention With First- and Second-Generation Drug-Eluting Stents. Лот/Сйи&/, 2014, 113:1968-1976.

21. Stone GW, Maehara A, Lansky AJ et al. A Prospective Natural-History Study of Coronary Atherosclerosis. NEnglJ Med, 2011,364: 226-35.

22. Xie Y, Mintz GS, Yang J et al. Clinical Outcome of Nonculprit Plaque Ruptures in Patients With Acute Coronary Syndrome in the PROSPECT Study.JAm Coll CardiolImg, 2014,7: 397-405.

23. Mauri L, Kereiakes DJ, Yeh RW. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N EnglJMed, 2014, 371: 2155-66.

24. Bonaca MP, Bhatt DL, Cohen M et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N EnglJMed. DOI: 10.1056/NEJMoa1500857.

25. Aradi D, Komуcsi A, Price MJ et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. IntJ Cardiol, 2013. Sep 1. 167(5): 2140-8. doi: 10.1016/j.ijcard.2012.05.100.

26. Комаров А.Л., Панченко Е.П., Донников А.Е., Шахматова О.О., Джалилова Г.В., Илющенко Т.А. Факторы, определяющие клиническую эффективность клопидогрела и прогноз у больных стабильной формой ишемичес-кой болезни сердца. Кардиология, 2011, 2: 8-18.

27. Price MJ, Berger PB, Teirstein PS et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneouscoronary intervention: the GRAVITAS randomized trial.JAMA, 2011. Mar 16, 305(11): 1097-105. doi: 10.1001/jama.2011. 290.

28. Price MJ, Angiolillo DJ, Teirstein PS et al. Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention. A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial. Circulation, 2011, 124: 1132-1137.

29. Collet JP, Cuisset T, RangО G, et al for the ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. NEnglJ Med, 2012, 367:2100-9.

30. Parodi G, Marcucci R, Valenti R et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.JAmMedAssoc, 2011, 306:1215-1223.

31. Aradi D, Tornyos A, Pinter T et al. Optimizing P2Y-recep-tor inhibition in acute coronary syndrome patients based on platelet function testing: impact of prasugrel and high-dose clopidogrel.JAm Coll Cardiol, 2014, Mar 25, 63(11): 1061-70. doi: 10.1016/j.jacc.2013.12.023.

32. Mayer K, Schulz S, Bernlochner I et al. A comparative cohort study on personalized antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivi-

33. ty. Results of the ISAR-HPR registry. Thromb Haemost, 2014, 112:342-351.

34. Siller-Matula JM, Francesconi M, Dechant C et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. IntJ Cardiol, 2013. 167: 2018-2023.

35. Price MJ, Murray SS, Angiolillo DJ, et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. JAm Coll Cardiol, 2012, May 29, 59(22): 1928-37.

36. Гуськова Е.В., Панченко Е.П., Комаров А.Л., Добровольский А.Б., Самко А.Н. Остаточная реактивность тромбоцитов к АДФ и риск кровотечений у больных стабильной ИБС, получающих двойную антитромбоци-тарную терапию в связи с плановым чрескожным коронарным вмешательством.

37. Mega JL, Hochholzer W, Frelinger AL et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.JAMA, 2011, 306(20): 2221-2228.

38. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N EnglJMed, 2009, 361.

39. Karve AM, Seth M, Sharma M. Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). AmJ Cardiol, 2015. Jun 1.и 115(11): 1502-6. doi: 10.1016/j.amjcard. 2015.02.049.

40. Damman P, Varenhorst C, Koul S et al. Treatment Patterns and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Treated With Prasugrel or Clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]). AmJ Cardiol, 2014, 113: 64e69.

41. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study. http://acc.sagepub.com/con-tent/early/2014/11/20/2048872614560505.

42. S Gandhi, B Zile, M K. Tan. Increased Uptake of Guideline Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective. CanadianJournal of Cardiology, 2014. doi: 10.1016/j.cjca. 2014.09.011.

43. Эрлих А.Д., Мацкеплишвили С.Т., Грацианскии Н.А., Бу-зиашвили Ю.И. и все участники московского регистра ОКС. Первыи московскии регистр острого коронарного синдрома: характеристика больных, лечение и исходы за время пребывания в стационаре. Кардиоло-гия, 2013, 12:4-13.

44. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol, 2012, 59: 2159-64.


Для цитирования:


КОМАРОВ А.Л. ОЦЕНКА ЧУВСТВИТЕЛЬНОСТИ К КЛОПИДОГРЕЛУ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ. Атеротромбоз. 2015;(2):95-106. https://doi.org/10.21518/2307-1109-2015-2-95-106

For citation:


Komarov A.L. EVALUATION OF SENSITIVITY TO CLOPIDOGREL: THE CURRENT STATE OF THE PROBLEM. Atherothrombosis. 2015;(2):95-106. (In Russ.) https://doi.org/10.21518/2307-1109-2015-2-95-106

Просмотров: 356


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)